Kelly Davio

Articles

Splenomegaly Linked With Thrombosis, Cardiovascular Risk for Patients With ET and PV

January 02, 2020

Splenomegaly, or enlargement of the spleen, is common in patients with Philadelphia-negative myeloproliferative neoplasms, and it is associated with symptoms like early satiety and abdominal pain. The role that splenomegaly has in terms of quality of life and prognosis in primary myelofibrosis is fairly well understood, but it has been less frequently investigated among patients with essential thrombocythemia (ET) and polycythemia vera (PV).

Lumasiran Meets Primary End Point in Phase 3 Study in Patients With PH1

December 25, 2019

Drug maker Alnylam Pharmaceuticals has announced that the ILLUMINATE-A trial, a phase 3 study of lumasiran, an investigational RNA interference product targeting glycolate oxidase, met its primary end point in a study of patients with primary hyperoxaluria type 1 (PH1).

As Healthcare Embraces Digital Solutions, Building Trust With Patients Is Key

November 11, 2019

As healthcare companies, tech firms, and startups seek to use digital tools to help individuals manage their health, patients have growing concerns about how their data are used. During a panel discussion during the opening day of the FT Global Pharmaceutical and Biotechnology Conference 2019, held this week in London, United Kingdom, executives from across the pharmaceutical and digital health spaces discussed the critical importance of building relationships with patients as a means to not only reap high-quality data, but also improve patients’ outcomes and save healthcare systems money.